Country: Kenya

Pandemic-related resilience in HPV vaccination programmes – Perspectives from selected countries in Africa on what it will take to vaccinate 90% of girls by 2030

In this series of five country case studies, Kouassi and colleagues document how Côte d’Ivoire, Kenya, Liberia, Zambia, and Senegal maintained and recovered their HPV vaccination programmes following COVID-19 disruptions. Common challenges included school closures, misinformation conflating HPV and COVID-19 vaccines, and competing health priorities that diverted staff and funding. Enabling factors included strong Ministry […]

Routine HPV vaccination: Reflection on delivery strategies based on countries’ experiences

In this commentary, Waheed and colleagues reflect on HPV vaccine delivery strategies across several low- and middle-income countries, comparing country experiences against existing WHO guidelines. Three delivery approaches are documented: routinized campaign-mode vaccination using schools as the primary site (The Gambia, Zambia, Ethiopia), routine health facility services complemented by community and school outreach (Tanzania, Kenya, […]

Effective communication by health care workers to promote HPV vaccination: Lessons learned from Kenya, India, and Nigeria

In this case study analysis, Njogu and colleagues examine how health care workers in Kenya, India, and Nigeria have communicated to promote HPV vaccine uptake at different stages of national rollout. In Kenya, a multisectoral approach and myth-busting training proved critical; in Sikkim (India), intensive social mobilization and cascade training underpinned a successful subnational introduction; […]

Mot de bienvenue

Paul Nyai, représentant de Jhpiego, ouvre le symposium CHIC au Kenya en accueillant des ministères de la santé, chercheurs et partenaires internationaux. Il présente la rencontre comme une plateforme visant à faire progresser des programmes de vaccination HPV durables en Afrique, à travers la collaboration entre politiques, recherche et mise en œuvre. L’accent est mis […]

Discours d’ouverture

Le Dr Patrick Amoth, Directeur général de la santé au ministère de la Santé du Kenya, a ouvert la session en soulignant le fardeau persistant du cancer du col de l’utérus malgré son caractère évitable. Il a mis en avant les progrès du Kenya, notamment l’augmentation de la couverture vaccinale et la transition vers une […]

Panorama situationnel du HPV – Kenya

Depuis le déploiement national, 3,6 millions de filles ont reçu la première dose et 2,5 millions ont complété le schéma à deux doses avec le vaccin quadrivalent Gardasil. La prestation de services combine la vaccination en établissement, des activités de proximité scolaire et des équipes mobiles communautaires pour atteindre les filles non scolarisées. Les données […]

Efficacy Of Quadrivalent Human Papillomavirus Vaccine Among Kenyan Adolescents And Young Adults Living With HIV Nine Years After Initial Vaccination

In Kenya, a nine-year follow-up of a cohort of 180 adolescents living with HIV who received three doses of the quadrivalent HPV vaccine at ages 9–14 found sustained vaccine-specific protection, with zero persistent infections detected for HPV types 11, 16, or 18 among 151 evaluable participants. Only two participants (1.3%) had any vaccine-genotype persistent infection, […]

>